Professor Kim Dong-hyun of the Department of Ophthalmology at 高丽大学安岩医院 and the research team of RudaCure Inc. (CEO: Yongho Kim) have demonstrated the 眼内压-related safety of 'RCI001,' a novel treatment for 炎症 眼部 diseases.
In a recent animal study, Professor Kim's research team administered a steroid formulation and RCI001 three times daily for five weeks, then compared 眼内压 and 眼表面 status. While five weeks of RCI001 administration did not cause any elevation in 眼内压 or changes in the 眼表面, corticosteroid administration resulted in an approximately 38% increase in 眼内压 compared to baseline.
Professor Kim stated, "Steroid formulations have historically been difficult to use long-term in clinical practice due to the risk of complications," adding, "This study has shown that RCI001 holds promise as an effective long-term 抗炎 agent for chronic 眼表面疾病 requiring extended treatment, such as 干眼症 and 干燥综合征, and I expect it to be of great benefit to patients in the future."
This research was published in the October 2023 issue of the international academic journal Frontiers under the title 'Comparison of RCI001 and corticosteroid on the effects on 眼内压 in mice.'
Husaeng Ilbo: http://www.whosaeng.com/147434
Edaily: https://m.edaily.co.kr/news/read?newsId=02624006635774232&mediaCodeNo=257
Nate News: https://news.nate.com/view/20231018n12860?mid=n1101